Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay

Journal of Pharmacology and Experimental Therapeutics

Volumn 358, Issue 3, 2016, Pages 580-587

  Martínez Pinilla, Eva ^a,b   Rabal, Obdulia ^a   Reyes Resina, Irene ^c,d   Zamarbide, Marta ^a   Navarro, Gemma ^c,d   Sánchez Arias, Juan A ^a   De Miguel, Irene ^a   Lanciego, José L ^a,d,e   Oyarzabal, Julen ^a   Franco, Rafael ^c,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^e IdiSNA Navarra Institute for Health Research   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CM 157; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 56; TH CHRYSENEDIOL; UNCLASSIFIED DRUG; CHRYSENE DERIVATIVE; FLUORESCENT DYE; GPR55 PROTEIN, HUMAN; INDOLE DERIVATIVE; IODOPRAVADOLINE; LIGAND; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EMBRYO; FLUORESCENCE RESONANCE ENERGY TRANSFER; HOMOGENEOUS TIME RESOLVED FLUORESCENCE RECEPTOR BINDING ASSAY; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN QUATERNARY STRUCTURE; RECEPTOR BINDING ASSAY; BINDING SITE; BIOASSAY; CHEMISTRY; HEK293 CELL LINE; METABOLISM; MOLECULAR DOCKING; PROTEIN MULTIMERIZATION; STRUCTURE ACTIVITY RELATION;

BINDING SITES; BIOLOGICAL ASSAY; CHRYSENES; FLUORESCENT DYES; HEK293 CELLS; HUMANS; INDOLES; LIGANDS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84983762729     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.234948     Document Type: Article

References (32)

1. Atwood BK, Straiker A, and Mackie K (2012) CB2: Therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry 38:16-20.
2. Baba K, Benleulmi-Chaachoua A, Journé AS, Kamal M, Guillaume JL, Dussaud S, Gbahou F, Yettou K, Liu C, Contreras-Alcantara S, et al. (2013) Heteromeric MT1/MT2 melatonin receptors modulate photoreceptor function. Sci Signal 6:89.
3. Balenga NA, Martínez-Pinilla E, Kargl J, Schröder R, Peinhaupt M, Platzer W, Bálint Z, Zamarbide M, Dopeso-Reyes I, Ricobaraza A, et al. (2014) Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signaling. Br J Pharmacol 171:5387-5406.
4. Bolognini D, Cascio MG, Parolaro D, and Pertwee RG (2012) AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol 165:2561-2574.
5. Buckley NE (2008) The peripheral cannabinoid receptor knockout mice: An update. Br J Pharmacol 153:309-318.
6. Bushlin I, Gupta A, Stockton SD Jr, Miller LK, and Devi LA (2012) Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain. PLoS One 7:e49789.
7. Callén L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallol J, Casadó V, Lanciego JL, Franco R, Lluis C, et al. (2012) Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 287:20851-20865.
8. Campillo NE and Páez JA (2009) Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease. Mini Rev Med Chem 9:539-559.
9. Carai MAM, Colombo G, Maccioni P, and Gessa GL (2006) Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 12:91-99.
10. Ellis J, Pediani JD, Canals M, Milasta S, and Milligan G (2006) Orexin-1 receptorcannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281:38812-38824.
11. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, et al. (2009) Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5:131-134.
12. Gijsen HJM, De Cleyn MAJ, Surkyn M, Verbist BMP (2008) inventors, Janssen Pharmaceutica NV, assignee. Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group. PatentWO2008003665. 2008 Jan 10.
13. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, Kanaide M, Taniyama K, Sumikawa K, and Uezono Y (2008) mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: Electrophysiological and FRET assay analysis. J Pharmacol Sci 108:308-319.
14. Idris AI (2010) Cannabinoid receptors as target for treatment of osteoporosis: A tale of two therapies. Curr Neuropharmacol 8:243-253.
15. Kon IK, Matsumizu M, Shima A (2006) inventors, Pfizer Japan Inc., assignee. Sulfonyl benzimidazole derivatives. PatentWO2006048754. 2006 May 11.
16. Landsman RS, Makriyannis A, Deng H, Consroe P, Roeske WR, and Yamamura HI (1998) AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci 62:PL109-PL113.
17. Leleu-Chavain N, Desreumaux P, Chavatte P, and Millet R (2013) Therapeutical potential of CB2 receptors in immune-related diseases. Curr Mol Pharmacol 6: 183-203.
18. Levoye A, Dam J, Ayoub MA, Guillaume JL, Couturier C, Delagrange P, and Jockers R (2006) The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J 25:3012- 3023.
19. Malek N, Popiolek-Barczyk K, Mika J, Przewlocka B, and Starowicz K (2015) Anandamide, acting via CB2 receptors, alleviates LPS-induced neuroinflammation in rat primary microglial cultures. Neural Plast 2015:130639.
20. Martínez-Pinilla E, Reyes-Resina I, Oñatibia-Astibia A, Zamarbide M, Ricobaraza A, Navarro G, Moreno E, Dopeso-Reyes IG, Sierra S, Rico AJ, et al. (2014) CB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Exp Neurol 261:44-52.
21. Navarro G, Carriba P, Gandía J, Ciruela F, Casadó V, Cortés A, Mallol J, Canela EI, Lluis C, and Franco R (2008) Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. Scientific World Journal 8:1088-1097.
22. Omori Y, Nakamura K, Yamashita S, Matsuda H, Mizutani T, Miyamoto K, and Minegishi T (2005) Effect of follicle-stimulating hormone and estrogen on the expression of betaglycan messenger ribonucleic acid levels in cultured rat granulosa cells. Endocrinology 146:3379-3386.
23. Pertwee R, Griffin G, Fernando S, Li X, Hill A, and Makriyannis A (1995) AM630, a competitive cannabinoid receptor antagonist. Life Sci 56:1949-1955.
24. Przybyla JA and Watts VJ (2010) Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers. J Pharmacol Exp Ther 332:710-719.
25. Rabal O and Oyarzabal J (2012) Biologically relevant chemical space navigator: from patent and structure- Activity relationship analysis to library acquisition and design. J Chem Inf Model 52:3123-3137.
26. Rios C, Gomes I, and Devi LA (2006) mu Opioid and CB1 cannabinoid receptor interactions: Reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148:387-395.
27. Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A, and Pertwee RG (1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 126: 665-672.
28. Sam AH, Salem V, and Ghatei MA (2011) Rimonabant: from RIO to ban. J Obes 2011: 432607.
29. Savonenko AV, Melnikova T, Wang Y, Ravert H, Gao Y, Koppel J, Lee D, Pletnikova O, Cho E, Sayyida N, et al. (2015) Cannabinoid CB2 receptors in a mouse model of Ab amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One 10:e0129618.
30. Sun YX, Xu AH, Yang Y, Zhang JX, and Yu AW (2015) Activation of cannabinoid receptor 2 enhances osteogenic differentiation of bone marrow derived mesenchymal stem cells. BioMed Res Int 2015:874982.
31. Tao Q, McAllister SD, Andreassi J, Nowell KW, Cabral GA, Hurst DP, Bachtel K, Ekman MC, Reggio PH, and Abood ME (1999) Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): Evidence for subtype specificity. Mol Pharmacol 55:605-613.
32. Zhang RX, Ren K, and Dubner R (2013) Osteoarthritis pain mechanisms: basic studies in animal models. Osteoarthritis Cartilage 21:1308-1315.